ADMA Biologics (NASDAQ:ADMA) Trading Up 7.6% – What’s Next?

ADMA Biologics Inc (NASDAQ:ADMA) shares shot up 7.6% on Wednesday . The company traded as high as $8.77 and last traded at $8.7350. 314,986 shares traded hands during trading, a decline of 94% from the average session volume of 5,151,083 shares. The stock had previously closed at $8.12.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ADMA. Zacks Research lowered shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 26th. Raymond James Financial initiated coverage on shares of ADMA Biologics in a research report on Wednesday. They set an “outperform” rating and a $21.00 price target for the company. Canaccord Genuity Group reduced their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Finally, Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, ADMA Biologics presently has a consensus rating of “Hold” and an average price target of $19.67.

ADMA Biologics Stock Performance

The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. The business’s fifty day simple moving average is $9.22 and its 200-day simple moving average is $14.31. The firm has a market capitalization of $1.99 billion, a PE ratio of 12.64 and a beta of 0.72.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting analysts’ consensus estimates of $0.19. The firm had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The company’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.11 EPS. As a group, equities research analysts expect that ADMA Biologics Inc will post 0.84 EPS for the current year.

Insider Activity at ADMA Biologics

In other news, Director Jerrold B. Grossman bought 12,500 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the transaction, the director owned 513,884 shares of the company’s stock, valued at $4,116,210.84. The trade was a 2.49% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 3.90% of the company’s stock.

Institutional Trading of ADMA Biologics

Institutional investors have recently bought and sold shares of the stock. Summit Securities Group LLC bought a new stake in ADMA Biologics in the fourth quarter worth $29,000. Rothschild Investment LLC lifted its position in ADMA Biologics by 373.8% in the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,495 shares during the last quarter. Optima Capital LLC purchased a new stake in ADMA Biologics in the fourth quarter worth $36,000. Clearstead Advisors LLC increased its stake in ADMA Biologics by 55.7% in the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 795 shares during the period. Finally, iSAM Funds UK Ltd purchased a new stake in ADMA Biologics in the third quarter worth $34,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.